COYA vs LRCX · rev $7.9M vs P/E 71, rev $23.23B
Coya Therapeutics, Inc. Common Stock (COYA) versus Lam Research Corp (LRCX) — a side-by-side from cached financials, not a winner call.
Coya Therapeutics, Inc. Common Stock (COYA) is a biotechnology company listed on NASDAQ.
Lam Research Corp (LRCX) is a semiconductor equipment & materials company listed on NASDAQ. It is led by Timothy M. Archer.
Latest reported COYA revenue for 2025-12-31 was $7.9M. Net income was -$21.2M. Revenue was up 123.6% from 2024-12-31 to 2025-12-31. COYA currently screens at market cap $118.0M.
Latest reported LRCX revenue for 2026-06-28 was $23.23B. Net income was $7.27B. LRCX currently screens at market cap $467.94B and trailing P/E 70.9.
COYA currently screens at market cap $118.0M. LRCX currently screens at market cap $467.94B and trailing P/E 70.9.
Not investment advice. Open the COYA and LRCX stock pages for the full models.
Not investment advice.